Dear Editor, Cutaneous involvement in multiple myeloma (MM) is uncommon. Generally, it occurs in the late stage of the disease and is considered a sign of poor prognosis. Its pathogenesis is not entirely clear. Changes in adhesion molecule expression, especially with regard to CD138 and CD56 antigens, could contribute to different plasma cell migration and homing [1] ; therefore, a possible association between the malignant plasma cell immunophenotype and skin infiltration is debated. We report a case of skin lesions from an IgA MM patient who was successfully treated with bortezomib and dexamethasone.
On October 2004, a 69-year-old woman was admitted to our centre for a recent and fortuitous finding of a serum monoclonal protein. A diagnosis of MM IgA kappa stage IIA, according to Durie and Salmon classification, was made. The patient received six monthly cycles of the melphalan, prednisone and thalidomide regimen [2] , which resulted in a clinical complete response (CR) [3] . Therefore, she received a daily dose (100 mg) of thalidomide as maintenance therapy. On January 2006, this therapy was reduced (50 mg/day) for neurological toxicity (paresthesia grade 2 World Health Organisation) and, on June 2006, was interrupted for a Sjogren-like syndrome with an ocular dryness unresponsive to treatment.
On September 2006, the patient observed the growth of a nodular non-pruriginous skin lesion of up to 0.5 cm in diameter on her back. A biopsy revealed the infiltration of superficial and deep dermis with uniform plasmacytoid cells strongly positive for CD79a, CD138 antigens, presenting a kappa light chain restriction (Fig. 1) .
Restaging of the disease showed no evidence of monoclonal protein and normal serum immunoglobulin levels. Bone marrow aspirate and trephine revealed a normal cellular pattern with no morphological or immunophenotypic evidence of MM. Bone skeletal X-rays were negative. There were no other systemic signs of MM underlying the skin lesion. During the restaging, four new nodular lesions appeared in the same place of the first. Because of the older age and the previous treatment, the patient underwent a therapy including bortezomib (1.3 mg/m 2 on days1, 4, 8, 11) and dexamethasone (20 mg on days1-4) every 21 days for four cycles. During the third and fourth cycle, bortezomib dosage was reduced to 25% and 50%, respectively, because of peripheral neuropathy (pain and paresthesias grade 3 National Cancer Institute). No other toxicity was observed. After two cycles, the cutaneous lesions disappeared. No maintenance therapy was performed. After 2 years, the patient remains in haematological and cutaneous CR. In this report, we describe a case of cutaneous plasma cell lesions in a patient previously treated with thalidomide. Avigdor et al. report another case of resistant MM treated with thalidomide that developed cutaneous plasmacytoma in the absence of systemic signs of disease and suggest a possible correlation between the biological modifications induced by thalidomide and an unusual more aggressive course of the disease [4] . The treatment of cutaneous plasmacytoma is still controversial. Bortezomib is a potent and selective proteasome inhibitor recently introduced in the treatment of patients with relapsed/refractory MM. A significant activity of bortezomib in soft tissue plasmacytoma is reported [5] , but there are no experiences in cutaneous plasmacytoma. In conclusion, bortezomib, in our case, revealed to be effective and manageable in the treatment of skin lesions from MM, suggesting its possible employment in cutaneous plasmacytoma. 
